Scotland's MGB Plots Phase III For Promising Antibacterial
Potential Gold Standard For C Diff
Executive Summary
With a late-stage compound on its hands, MGB is currently in discussions with several biotech and pharma companies and also with venture capitalists to continue late-stage development of a novel antibiotic which could transform treatment of Clostridium difficile.